RE: Topped up15 Oct 2020 20:02
SNG: The business, focused primarily on lung viral defence in asthma, COPD and COVID-19, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease
Admission of the Firm Placing Shares and Option Shares to trading on AIM and commencement of dealings
8.00 a.m. on 19 October 2020
So, we'd get an RNS on Monday.
NB: this is pure conjecture and almost certainly won't be a VELA investment.